Bernstein analyst Lance Wilkes upgrades $Humana (HUM.US)$ to a buy rating, and adjusts the target price from $405 to $308.
According to TipRanks data, the analyst has a success rate of 71.7% and a total average return of 14.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Humana (HUM.US)$'s main analysts recently are as follows:
The assessment of Humana's financial outlook has seen a revision, with expectations for FY26 EPS being adjusted following the company's recent 8-K, which highlighted a decline in star ratings based on preliminary Medicare Advantage performance data. Nevertheless, the current valuation takes into account the company's mitigation initiatives planned for 2027, as well as the possible positive outcomes from pending appeals.
Despite Humana's capability to annually reprice its Medicare Advantage plans and the potential to enhance star ratings each year, the company's overall path to recovery is now perceived as overly complex. The timeline for regaining normalized margins could extend past 2027 unless there are effective appeals for star ratings.
The most significant factor for Humana is the Medicare Advantage stars appeal. While the company's third quarter performance is satisfactory, an unsuccessful appeal is being factored into forecasts, which suggests that even projected 2027 earnings per share may not surpass those of 2024.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
联博集团分析师Lance Wilkes上调$哈门那 (HUM.US)$至买入评级，并将目标价从405美元下调至308美元。
根据TipRanks数据显示，该分析师近一年总胜率为71.7%，总平均回报率为14.3%。
此外，综合报道，$哈门那 (HUM.US)$近期主要分析师观点如下：
对Humana财务前景的评估进行了修订，继该公司最近的8k之后，对26财年每股收益的预期进行了调整，该指数突显了根据Medicare Advantage的初步业绩数据得出的星级评级下降。尽管如此，目前的估值考虑了该公司计划于2027年采取的缓解举措，以及未决上诉可能产生的积极结果。
尽管Humana有能力每年对其Medicare Advantage计划进行重新定价，并且有可能每年提高星级评级，但该公司的整体复苏之路现在被认为过于复杂。除非对星级评级提出有效呼吁，否则恢复正常利润率的时间表可能会延至2027年以后。
对Humana来说，最重要的因素是Medicare Advantage明星的吸引力。尽管该公司第三季度的业绩令人满意，但预测中考虑了上诉失败的因素，这表明即使是预计的2027年每股收益也可能无法超过2024年的水平。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
